Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
2500 participants
OBSERVATIONAL
2019-11-08
2022-11-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
NGS-based Comprehensive Genomic ctDNA Panel in NSCLC With Immunotherapy
NCT04636047
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS
NCT03172156
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage II to IIIA NSCLC by NGS
NCT03465241
Clinical Evaluation of Genetron Lung Cancer Panel in Non-small Cell Lung Cancer Patients
NCT05023746
A Comprehensive Evaluation of Circulating Tumor DNA and Circulating Tumor Cells as a Predictive Marker in Lung Cancer
NCT04254497
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Firstly, 2500 cases of lung cancer tumor tissue samples will be collected according to the Inclusion Criteria.
Secondly，samples will be sequenced through high throughput sequencing by ChosenMed Technology (Beijing) Co., Ltd., according to the strict process. Panel sequencing of the samples will be carried out through Illumina platform. After targeting Panel sequencing, four types of mutations including point mutation, insertion deletion, gene fusion and copy number variation will be detected, and tumor mutation burden as well as microsatellite instability will be evaluated. Combined with the bioinformatics analysis and sequencing results of the samples, the gene map of lung cancer in China will be drawn up, and the specific multigene panel of lung cancer for the Chinese population will be established as the basis for the subsequent clinical screening of molecular markers related to targeting therapy, immunotherapy and prognosis.
Thirdly, patients will be followed up on the information related to treatment after sequencing. According to the genetic information of the patients, the curative effect and prognosis of the patients will be followed up every three to six months. The follow-up time includes at least the first treatment plan after the patients' detection, which may continue until the final survival time of the patients, and explore the molecular markers and combinations that can affect the curative effect and prognosis of patients with lung cancer.
Finally, the clinical data and specimen information of patients will be managed and analyzed by Excel. Multivariate Cox regression analysis will be used to explore the clinical, pathological and molecular markers that affect the prognosis and curative effect of lung cancer, and draw the survival curve with the statistically significant indicators so as to provide reliable statistical results for the following clinical guidance.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Stage Ⅲ or Ⅳ non-small cell lung cancer and should to receive tyrosine kinase inhibitors or immune checkpoint inhibitors for the first-line or adjuvant treatment
3. Able to provide 10ml anticoagulant peripheral blood and tumor tissue which should meet at least one of the following requirements: fresh tissue samples (≥ 1cm, at least 2 pieces) obtained by operation (1 piece, soybean size) or needle biopsy, 2 pieces of bronchoscopic biopsy tissue, paraffin section (thickness of 4-8 μm, operation or biopsy samples, ≥ 10 pieces, unstained)
4. Able to provide basic clinical and pathological data
5. Must be willing to be followed up
Exclusion Criteria
2. Stage I or II non-small cell lung cancer
3. Be not able to provide enough peripheral blood or tumor tissue
4. Incomplete basic clinical data
5. Unwilling to be followed up
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ChosenMed Technology (Beijing) Co.,Ltd
UNKNOWN
Xuanwu Hospital, Beijing
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiuyi Zhi, M.D.
Role: PRINCIPAL_INVESTIGATOR
Xuanwu Hospital, Beijing
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Guangzhou Institute of Respiratory Health
Guangzhou, Guangdong, China
Affiliated Hospital of Hebei University
Baoding, Hebei, China
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The Second Hospital Affiliated to Harbin Medical University
Harbin, Heilongjiang, China
Cancer Hospital Affiliated to Harbin Medical University
Harbin, Heilongjiang, China
The Second Hospital Affiliated to Harbin Medical University
Harbin, Heilongjiang, China
The First Hospital of Jilin University
Changchun, Jilin, China
Sino-Japan Friendship Hospital, Jilin University
Changchun, Jilin, China
The Third Hospital of Jilin University
Changchun, Jilin, China
The First Hospital Affiliated to Dalian Medical University
Dalian, Liaoning, China
General Hospital of the Northern Theater of Chinese PLA
Shenyang, Liaoning, China
The First Hospital Affiliated to China Medical University
Shenyang, Liaoning, China
Liaoning Cancer Hospital
Shenyang, Liaoning, China
Qilu Hospital, Shandong University
Jinan, Shandong, China
Shandong Provincial Hospital
Jinan, Shangdong, China
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
The Second Affiliated Hospital of Zhejiang University School of Medicine (Binjiang District)
Hangzhou, Zhejiang, China
The Second Affiliated Hospital of Zhejiang University School of Medcine (Headquarters)
Hangzhou, Zhejiang, China
Hwa Mei Hospital, University of Chinese Academy of Sciences
Ningbo, Zhejiang, China
The Fourth Medical Center of PLA General Hospital
Beijing, , China
Beijing Friendship Hospital, Capital Medical University
Beijing, , China
Xuanwu Hospital,Beijing
Beijing, , China
Air Force Specialized Medical Center
Beijing, , China
Air Force Specialized Medical Center
Beijing, , China
Peking University Cancer Hospital
Beijing, , China
The Seventh Medical Center of PLA General Hospital
Beijing, , China
Beijing Hospital
Beijing, , China
Chinese PLA General Hospital
Beijing, , China
Chinese PLA General Hospital
Beijing, , China
Beijing Chest Hospital, Capital Medical University
Beijing, , China
Renji Hospital,Shanghai Jiaotong University School of Medicine
Shanghai, , China
Lung Hospital Affiliated to Shanghai Tongji Medical University
Shanghai, , China
General Hospital of Tianjin Medical University
Tianjin, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yuansong Bai, M.D.& Ph.D.
Role: primary
Yue Wang, M.D. & Ph.D.
Role: primary
Hui Tian, M.D. & Ph.D.
Role: primary
Zhongmin Peng, M.D. & Ph.D.
Role: primary
Yi Zhang, M.D.
Role: primary
Yi Liu, M.D.& Ph.D.
Role: primary
Xiangyang Chu, M.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YCZYPT[2018]06-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.